Medicare selects Botox and Trulicity among 15 high-cost drugs for price negotiations under new federal authority, with lower prices expected in 2028.
The National Institute for Occupational Safety and Health (NIOSH) has published the 2024 update to its List of Hazardous Drugs in Healthcare Settings, marking the first revision since 2016. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results